{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T06:35:40Z","timestamp":1757313340797,"version":"3.37.3"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005187","name":"University of Athens","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005187","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hormones"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s42000-023-00514-x","type":"journal-article","created":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T04:27:34Z","timestamp":1702528054000},"page":"415-417","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Non-alcoholic fatty liver disease in patients with type 2 diabetes: diagnostic and therapeutic considerations"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4973-0357","authenticated-orcid":false,"given":"Eleni-Maria","family":"Paraschou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0924-3642","authenticated-orcid":false,"given":"Almog","family":"Shalit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0651-1376","authenticated-orcid":false,"given":"Stavroula A.","family":"Paschou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,14]]},"reference":[{"key":"514_CR1","doi-asserted-by":"crossref","unstructured":"ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al (2023) Addendum. 4. Comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes\u20142023. Diabetes Care 2023;46(Suppl. 1):S49\u2013S67. Diabetes Care 25;46(9):1718\u201320","DOI":"10.2337\/dc23-ad09"},{"issue":"2","key":"514_CR2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/hep4.1618","volume":"5","author":"J Vieira Barbosa","year":"2020","unstructured":"Vieira Barbosa J, Lai M (2020) Nonalcoholic fatty liver disease screening in type 2 diabetes mellitus patients in the primary care setting. Hepatol Commun 5(2):158\u2013167. https:\/\/doi.org\/10.1002\/hep4.1618","journal-title":"Hepatol Commun"},{"issue":"2","key":"514_CR3","doi-asserted-by":"publisher","first-page":"346","DOI":"10.51821\/85.2.9775","volume":"85","author":"Q Binet","year":"2022","unstructured":"Binet Q, Loumaye A, Preumont V, Thissen JP, Hermans MP, Lanthier N (2022) Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients: what do we know so far? Acta Gastro-Enterol Belg 85(2):346\u201357. https:\/\/doi.org\/10.51821\/85.2.9775","journal-title":"Acta Gastro-Enterol Belg"},{"key":"514_CR4","doi-asserted-by":"publisher","first-page":"3920196","DOI":"10.1155\/2020\/3920196","volume":"2020","author":"DM Tanase","year":"2020","unstructured":"Tanase DM, Gosav EM, Costea CF, Ciocoiu M, Lacatusu CM, Maranduca MA et al (2020) The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD). J Diabetes Res 2020:3920196. https:\/\/doi.org\/10.1155\/2020\/3920196","journal-title":"J Diabetes Res"},{"key":"514_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12902-022-00980-1","volume":"22","author":"S Pouwels","year":"2022","unstructured":"Pouwels S, Sakran N, Graham Y, Leal A, Pintar T, Yang W et al (2022) Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord 22:63. https:\/\/doi.org\/10.1186\/s12902-022-00980-1","journal-title":"BMC Endocr Disord"},{"issue":"5","key":"514_CR6","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"K Cusi","year":"2022","unstructured":"Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT et al (2022) American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract 28(5):528\u2013562. https:\/\/doi.org\/10.1016\/j.eprac.2022.03.010","journal-title":"Endocr Pract"},{"issue":"5","key":"514_CR7","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D et al (2023) Hepatology 77(5):1797. https:\/\/doi.org\/10.1097\/HEP.0000000000000323","journal-title":"Hepatology"},{"issue":"4","key":"514_CR8","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/j.jhep.2022.06.016","volume":"77","author":"L Gracen","year":"2022","unstructured":"Gracen L, Hayward KL, Irvine KM, Valery PC, Powell EE (2022) Low accuracy of FIB-4 test to identify people with diabetes at low risk of advanced fibrosis. J Hepatol 77(4):1219\u20131221. https:\/\/doi.org\/10.1016\/j.jhep.2022.06.016","journal-title":"J Hepatol"},{"issue":"6","key":"514_CR9","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.jhep.2022.03.026","volume":"76","author":"QM Anstee","year":"2022","unstructured":"Anstee QM, Castera L, Loomba R (2022) Impact of non-invasive biomarkers on hepatology practice: past, present and future. J Hepatol 76(6):1362\u20131378. https:\/\/doi.org\/10.1016\/j.jhep.2022.03.026","journal-title":"J Hepatol"},{"issue":"9","key":"514_CR10","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1080\/17474124.2019.1649981","volume":"13","author":"M Arrese","year":"2019","unstructured":"Arrese M, Barrera F, Triantafilo N, Arab JP (2019) Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations. Expert Rev Gastroenterol Hepatol 13(9):849\u2013866. https:\/\/doi.org\/10.1080\/17474124.2019.1649981","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"2","key":"514_CR11","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.jhep.2017.11.028","volume":"68","author":"R Loomba","year":"2018","unstructured":"Loomba R (2018) Role of imaging-based biomarkers in NAFLD: recent advances in clinical application and future research directions. J Hepatol 68(2):296\u2013304. https:\/\/doi.org\/10.1016\/j.jhep.2017.11.028","journal-title":"J Hepatol"},{"issue":"10","key":"514_CR12","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1136\/gutjnl-2021-326874","volume":"71","author":"JF Dufour","year":"2022","unstructured":"Dufour JF, Anstee QM, Bugianesi E, Harrison S, Loomba R, Paradis V et al (2022) Current therapies and new developments in NASH. Gut 71(10):2123\u20132134. https:\/\/doi.org\/10.1136\/gutjnl-2021-326874","journal-title":"Gut"},{"key":"514_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.maturitas.2017.11.011","volume":"108","author":"P Anagnostis","year":"2018","unstructured":"Anagnostis P, Paschou SA, Goulis DG, Athyros VG, Karagiannis A (2018) Dietary management of dyslipidaemias. Is there any evidence for cardiovascular benefit? Maturitas 108:45\u201352. https:\/\/doi.org\/10.1016\/j.maturitas.2017.11.011","journal-title":"Maturitas"},{"issue":"5","key":"514_CR14","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.3390\/ijms22052350","volume":"22","author":"A Mantovani","year":"2021","unstructured":"Mantovani A, Dalbeni A (2021) Treatments for NAFLD: state of art. Int J Mol Sci 22(5):2350. https:\/\/doi.org\/10.3390\/ijms22052350","journal-title":"Int J Mol Sci"},{"key":"514_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1152042","author":"Z Yang","year":"2023","unstructured":"Yang Z, Wang L (2023) Current, emerging, and potential therapies for non-alcoholic steatohepatitis. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2023.1152042","journal-title":"Front Pharmacol"},{"issue":"11","key":"514_CR16","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.tem.2022.08.001","volume":"33","author":"E Hatziagelaki","year":"2022","unstructured":"Hatziagelaki E, Paschou SA, Sch\u00f6n M, Psaltopoulou T, Roden M (2022) NAFLD and thyroid function: pathophysiological and therapeutic considerations. Trends Endocrinol Metab 33(11):755\u2013768. https:\/\/doi.org\/10.1016\/j.tem.2022.08.001","journal-title":"Trends Endocrinol Metab"}],"container-title":["Hormones"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-023-00514-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s42000-023-00514-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-023-00514-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T07:17:12Z","timestamp":1727421432000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s42000-023-00514-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,14]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["514"],"URL":"https:\/\/doi.org\/10.1007\/s42000-023-00514-x","relation":{},"ISSN":["1109-3099","2520-8721"],"issn-type":[{"type":"print","value":"1109-3099"},{"type":"electronic","value":"2520-8721"}],"subject":[],"published":{"date-parts":[[2023,12,14]]},"assertion":[{"value":"15 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}